about
The prion hypothesis in Parkinson's disease: Braak to the futureThe role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.Tumor Necrosis Factor-α Underlies Loss of Cortical Dendritic Spine Density in a Mouse Model of Congestive Heart Failureα-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity.AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat.Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies.Dendritic spine density is altered in a mouse model of Cockayne syndrome.Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia.Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy.Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's diseaseInvestigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson’s DiseasePharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseRegulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's diseaseActigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation CarriersActions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted ratsGastrointestinal dysfunction in Parkinson's diseaseReply to: Gray et alBeyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbiditiesSynchrotron XRF imaging of Alzheimer's disease basal ganglia reveals linear dependence of high-field magnetic resonance microscopy on tissue iron concentrationIncreased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's diseaseIdentifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiologyAuthor response
P50
Q22001062-3A204DE1-0D00-4691-982B-A2AE1979852CQ35137388-5D55197D-A22A-4E46-9618-6BCA44EE5295Q36141418-48ABF93B-F310-48B8-82AA-444CE15665ACQ36685114-56F094BC-A0A2-4913-814E-D0C4564B324FQ37618665-7FB8098C-8A8F-471A-A6F3-3737C0165579Q38734429-9A477E76-E78F-48DD-BBF8-C917092250DAQ38806229-EDD2864B-D203-4CE3-A935-B9CA7AA3C6E1Q39998814-98E76E2B-DCE0-4D7D-A9BD-854CF194F90EQ43156735-03648D4C-48E4-4256-92F3-F4DE9F4DB6CAQ46177753-38EB78D0-15C7-4693-A1E9-488D3B367527Q46590408-40546DF7-DF03-49A9-8289-FFACE3731B7BQ46695376-FF4F5DD2-7D2E-4C68-9A0B-43B9019EB9DBQ46778260-3D4ED773-1A73-4200-8F85-4AFF452149F1Q47971420-2EEB5C3B-7D49-4241-87C1-CE23F4F2ECDBQ48348622-5416D507-A9D4-4C3A-A649-2184A17D6747Q48793592-89B7C363-FF31-4141-9CB3-3056CAAEB7D1Q48942905-3187AED6-886E-4106-809E-9A9FFBBC3B16Q62495777-B7F35A72-B664-46C9-A0A0-2989E26A4156Q62664872-95AADF59-D596-4149-9499-4204D8B003D4Q63498496-FAC3B516-5565-4856-AF39-6546D9035BF0Q64870243-34D83588-E01F-4CB7-945A-61E2B9422940Q64978439-143BB338-3A3C-4D71-B155-120EB9303F40Q79824323-FDAE8C6E-39C5-45E5-B286-0F8709605AC9Q87333322-122FC50E-0FAF-480D-9025-2C4EA646D848Q88072417-528BAEF3-3CEB-416F-ACD9-32E082747D8CQ90052900-D3F82AB9-FFDB-4E9D-8ACB-0208DCDEDB45Q92240703-C1C23CA4-74B0-4E40-9D2C-ABCF3D286A1EQ92834403-440821CA-CA17-4E73-8291-FFAAF7CEB08FQ94914694-79B4EF42-6909-4510-B5CA-5CAB55B45749Q95802081-B1CC1978-14C5-44A0-9D18-0AF4D17378CB
P50
description
researcher
@en
wetenschapper
@nl
name
Naomi P. Visanji
@en
Visanji NP
@nl
type
label
Naomi P. Visanji
@en
Visanji NP
@nl
altLabel
Visanji NP
@en
prefLabel
Naomi P. Visanji
@en
Visanji NP
@nl
P106
P31
P496
0000-0001-5968-7845